In vitro and in vivo studies of pharmacokinetics and antitumor efficacy of D07001-F4, an oral gemcitabine formulation

Cancer Chemotherapy and Pharmacology

Volumn 71, Issue 2, 2013, Pages 379-388

  Hsu, Kuang Yang ^b,c   Hao, Wei Hua ^a,c   Wang, Jong Jing ^a   Hsueh, Shu Ping ^a   Hsu, Pei Jing ^a   Chang, Li Chien ^b   Hsu, Chang Shan ^a  

^a InnoPharmax Inc 9F   (Taiwan)

^b NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Cytidine deaminase; D07001 F4; Gemcitabine; SMEDDS

Indexed keywords

ANTINEOPLASTIC AGENT; D 07001 F4; GEMCITABINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; COLON CANCER; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION; MITOSIS INHIBITION; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; TIME TO MAXIMUM PLASMA CONCENTRATION; TUMOR XENOGRAFT;

ADMINISTRATION, ORAL; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; CELL LINE, TUMOR; CHEMISTRY, PHARMACEUTICAL; DEOXYCYTIDINE; FEMALE; HUMANS; MICE; MICE, NUDE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84874106254     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-012-2017-5     Document Type: Article

References (27)

1. Information Product (2007) GEMZAR(R) IV injection, gemcitabine HCl IV injection. Eli Lilly and Company, Indianapolis, IN
2. Julka PK, Puri T, Rath GK (2006) A phase II study of gemcitabine and carboplatin combination chemotherapy in gallbladder carcinoma. Hepatobiliary Pancreat Dis Int 5:110-114
3. Dueñas-González A, Zarbá JJ, Patel F et al (2011) Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix. J Clin Oncol 29:1678-1685
4. Madajewicz S, Waterhouse DM, Ritch PS et al (2012) Multicenter, randomized phase II trial of bevacizumab plus folinic acid, fluorouracil, gemcitabine (FFG) versus bevacizumab plus folinic acid, fluorouracil, oxaliplatin (FOLFOX4) as first-line therapy for patients with advanced colorectal cancer. Invest New Drugs 30:772-778
5. Aurer I, Eghbali H, Raemaekers J et al (2011) Gem-(R)CHOP versus (R)CHOP: a randomized phase II study of gemcitabine combined with (R)CHOP in untreated aggressive non-Hodgkin's lymphoma-EORTC lymphoma group protocol 20021 (EudraCT number 2004-004635-54). Eur J Haematol 86:111-116
6. Brambilla L, Labianca R, Ferrucci SM et al (2001) Treatment of classical Kaposi's sarcoma with gemcitabine. Dermatology 202:119-122
7. Burris HA 3rd, Moore MJ, Andersen J et al (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:2403-2413
8. Rothenberg ML, Moore MJ, Cripps MC et al (1996) A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol 7:347-353
9. Cartwright TH, Cohn A, Varkey JA et al (2002) Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer. J Clin Oncol 20:160-164
10. Mackey JR, Yao SYM, Smith KM et al (1999) Gemcitabine transport in Xenopus oocytes expressing recombinant plasma membrane mammalian nucleoside transporters. J Natl Cancer Inst 91:1876-1881
11. Heinemann V, Hertel LW, Grindey GB et al (1988) Comparison of the cellular pharmacokinetics and toxicity of 2',2'-difluorodeoxycytidine and 1-ß-D-arabinofuranosylcytosine. Cancer Res 48:4024-4031
12. Huang P, Chubb S, Larry WLW et al (1991) Action of 2′,2′- difluorodeoxycytidine on DNA synthesis. Cancer Res 51:6110-6117
13. Plunkett W, Huang P, Xu YZ et al (1995) Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin Oncol 22:3-10
14. Heinemann V, Xu YZ, Chubb S, Sen A, Hertel LW, Grindey GB, Plunkett W (1990) Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2′,2′- difluorodeoxycytidine. Mol Pharmacol 38:567-572
15. Camiener GW, Smith CD (1965) Studies of the enzymatic deamination of cytosine arabinoside. I. Enzyme distribution and species specificity. Biochem Pharmacol 14:1405-1416
16. Veltkamp SA, Jansen RS, Callies S et al (2008) Oral administration of gemcitabine in patients with refractory tumors: a clinical and pharmacologic study. Clin Cancer Res 14:3477-3486
17. Jadhav KR, Shaikh IM, Ambade KW et al (2006) Applications of microemulsion based drug delivery system. Curr Drug Deliv 3:267-273
18. Xi J, Chang Q, Chan CK et al (2009) Formulation development and bioavailability evaluation of a self-nanoemulsified drug delivery system of oleanolic acid. AAPS Pharm Sci Tech 10:172-182
19. Beumer JH, Eiseman JL, Parise RA et al (2008) Modulation of gemcitabine (2′,2′-difluoro-2′-deoxycytidine) pharmacokinetics, metabolism, and bioavailability in mice by 3,4,5,6-tetrahydrouridine. Clin Cancer Res 14:3529-3535
20. Zhang L, Sinha V, Forgue ST et al (2006) Model-based drug development: the road to quantitative pharmacology. J Pharmacokinet Pharmacodyn 33:369-396
21. Guo F, Zhong H, He J et al (2011) Self-microemulsifying drug delivery system for improved oral bioavailability of dipyridamole: preparation and evaluation. Arch Pharm Res 34:1113-1123
22. Hao WH, Wang JJ, Lin TH et al (2009) Oral administration of gemcitabine (INNO-D07001) in beagle dogs: preliminary pharmacokinetic evaluation of gemcitabine and its metabolite. 2009 AAPS Annual Meeting and Exposition
23. Bergman AM, Pinedo HM, Peters GJ (2002) Determinants of resistance to 2′,2′-difluorodeoxycytidine (gemcitabine). Drug Resist Updat 5:19-33
24. Kroep JR, Loves WJP, van der Wilt CL et al (2002) Pretreatment deoxycytidine kinase levels predict in vivo gemcitabine sensitivity. Mol Cancer Ther 1:371-376
25. Nakahira S, Nakamori S, Tsujie M et al (2007) Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer. Int J Cancer 120:1355-1363
26. Bergman AM, Eijk PP, van Haperen VWTR et al (2005) In vivo induction of resistance to gemcitabine results in increased expression of ribonucleotide reductase subunit M1 as the major determinant. Cancer Res 65:9510-9516
27. Plunkett W, Huang P, Xu YZ et al (1995) Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin Oncol 22:3-10